SIBUTRAMINE HYDROCHLORIDE - Generic Drug Details

What are the generic sources for sibutramine hydrochloride and what is the scope of freedom to operate?

Sibutramine hydrochloride is the generic ingredient in one branded drug marketed by Abbott and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for sibutramine hydrochloride.

Summary for SIBUTRAMINE HYDROCHLORIDE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	6
Raw Ingredient (Bulk) Api Vendors:	159
Clinical Trials:	38
DailyMed Link:	SIBUTRAMINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for SIBUTRAMINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eurofarma Laboratorios S.A.	Phase 3
Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude	Phase 2
University of Calgary	Phase 4

See all SIBUTRAMINE HYDROCHLORIDE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for SIBUTRAMINE HYDROCHLORIDE

A08AA	Centrally acting antiobesity products
A08A	ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
A08	ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for SIBUTRAMINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MERIDIA	Capsules	sibutramine hydrochloride	10 mg and 15 mg	020632	1	2009-08-14

US Patents and Regulatory Information for SIBUTRAMINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	MERIDIA	sibutramine hydrochloride	CAPSULE;ORAL	020632-003	Nov 22, 1997		DISCN	No	No
Abbott	MERIDIA	sibutramine hydrochloride	CAPSULE;ORAL	020632-002	Nov 22, 1997		DISCN	No	No
Abbott	MERIDIA	sibutramine hydrochloride	CAPSULE;ORAL	020632-001	Nov 22, 1997		DISCN	No	No

Expired US Patents for SIBUTRAMINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbott	MERIDIA	sibutramine hydrochloride	CAPSULE;ORAL	020632-001	Nov 22, 1997
Abbott	MERIDIA	sibutramine hydrochloride	CAPSULE;ORAL	020632-002	Nov 22, 1997
Abbott	MERIDIA	sibutramine hydrochloride	CAPSULE;ORAL	020632-003	Nov 22, 1997
Abbott	MERIDIA	sibutramine hydrochloride	CAPSULE;ORAL	020632-003	Nov 22, 1997
Abbott	MERIDIA	sibutramine hydrochloride	CAPSULE;ORAL	020632-001	Nov 22, 1997
Abbott	MERIDIA	sibutramine hydrochloride	CAPSULE;ORAL	020632-002	Nov 22, 1997

SIBUTRAMINE HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for Sibutramine Hydrochloride?

Sibutramine hydrochloride was once a popular appetite suppressant marketed primarily for weight management. Its market presence declined after safety concerns prompted regulatory actions globally. The drug's decline illustrates key market dynamics:

• Regulatory bans and restrictions reduce demand and supply. In 2010, the U.S. Food and Drug Administration (FDA) revoked approval, citing increased cardiovascular risk. European authorities suspended its use in 2010.[1]

• Declining prescriptions and market share reflect safety warnings. Manufacturers withdrew products containing sibutramine voluntarily in some markets.

• Off-label use persists in certain regions where regulatory oversight is weaker. However, such markets experience limited growth potential.

• Alternative weight-loss treatments with better safety profiles, such as orlistat and liraglutide, gained market share, further shrinking sibutramine’s relevance.

• Patent expirations were less relevant because sibutramine was already off-patent before regulatory actions, limiting exclusivity-driven revenues.

• Existence of counterfeit and unregulated products containing sibutramine sustains certain illicit channels, although this activity does not significantly impact legitimate market size.

How Has the Financial Trajectory Evolved?

The financial history of sibutramine hydrochloride reflects regulatory setbacks and shifting market preferences:

• Peak sales occurred between 2005 and 2008. Estimated global sales ranged from $300 million to $500 million annually, primarily in North America and Europe.

• Post-2010 regulatory bans led to rapid revenue decline. Major pharmaceutical companies exited or suspended manufacturing for sibutramine products.

• The industry shifted focus to safer alternatives, causing a collapse of the former market niche. Sales diminished to negligible levels by 2012-2013.

• The contribution of sibutramine to company portfolios diminished sharply after 2010, with no new approved formulations or indications.

• Some companies explored repurposing or reformulating sibutramine derivatives but found limited success due to safety concerns and regulatory hurdles.

• Given its current regulatory status, the drug no longer presents as a viable commercial asset. Any ongoing revenue stems from counterfeit or unregulated markets, which are sporadic and unquantified.

How Do Regulatory Policies Shape the Market?

Regulatory authorities enforced bans based on safety data:

• FDA revoked approval in 2010 after the SCOUT trial linked sibutramine to increased cardiovascular events.[2]

• European Medicines Agency (EMA) suspended use in 2010, leading to withdrawal from the majority of European markets.

• Other regulators in Asia and Latin America issued warnings or banned sibutramine. Some countries still permit its use under strict medical supervision, but such markets are small.

• Regulatory actions have been consistent and aligned with public health priorities, effectively eliminating the formal commercial market.

What Are the Future Market Projections?

Considering current status, sibutramine hydrochloride has no meaningful market forecast:

• Limited production for illicit use persists but is untracked and insignificant in volume.

• No approved formulations or marketed products containing sibutramine are forthcoming due to safety concerns.

• Any future discussion centers on unauthorized or black-market activity rather than legitimate commercial expansion.

• The focus for companies involves developing new therapeutics with improved safety profiles for weight management.

Key Takeaways

• Regulatory actions in 2010 effectively eliminated the legal market for sibutramine hydrochloride, leading to sharp revenue declines.

• Sales peaked in mid-2000s at approximately $300–$500 million annually, then plummeted post-ban.

• The drug’s safety profile remains the primary barrier to market re-entry; no approved new formulations are in development.

• Off-label, unregulated markets persist in certain regions but remain a negligible component compared to the historic legitimate market.

• Future market development is centered on alternative therapies addressing obesity with improved safety and efficacy profiles.

FAQs

1. Could sibutramine hydrochloride return to the market?
Unlikely. Safety concerns outweigh benefits, and regulatory agencies maintain bans. Reformulation or new trials would be necessary but are improbable given current safety data.

2. Has any company attempted to reintroduce sibutramine?
There are no public records of recent attempts; past efforts ceased after regulatory bans. Black-market activity persists but holds little impact on legitimate markets.

3. Are there legal markets still operating with sibutramine?
Few, if any, countries permit legal sale. Some regions allow controlled, physician-supervised use but in practice, most markets are closed.

4. What alternatives replaced sibutramine?
Orlistat, phentermine, and liraglutide gained primary market positions, offering improved safety and efficacy.

5. Could new research reverse safety concerns?
Current safety profiles are well-documented; extensive re-evaluation would be required. The risk profile effectively precludes re-entry into the approved market.

---

Sources

[1] FDA, “Withdrawal of approval for weight loss products containing sibutramine,” 2010.
[2] SCOUT trial, “Cardiovascular outcomes in sibutramine-treated obese patients,” The New England Journal of Medicine, 2010.